Dr Reddy's Laboratories Ltd News

Dr Reddy's Laboratories Analyst Ratings

BenzingaJan 29 07:09 ET

Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating

MT NewswiresJun 1, 2023 09:37 ET

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $70

BenzingaJun 1, 2023 07:13 ET

Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating

MT NewswiresOct 25, 2022 07:10 ET

Barclays Maintains Overweight on Dr Reddy's Laboratories, Lowers Price Target to $66

Benzinga Real-time NewsOct 25, 2022 07:04 ET

Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 From $68, Maintains Overweight Rating

MT NewswiresSep 12, 2022 08:36 ET

Dr Reddy's Labs Is Maintained at Overweight by Barclays

Dow JonesSep 12, 2022 06:59 ET

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $69

Benzinga Real-time NewsSep 12, 2022 06:52 ET

Barclays Lowers Dr. Reddy's Laboratories' Price Target to $68 From $70, Maintains Overweight Rating

MT NewswiresJul 25, 2022 11:13 ET

Dr Reddy's Labs Price Target Cut to $68.00/Share From $70.00 by Barclays

Dow JonesJul 25, 2022 08:44 ET

Dr Reddy's Labs Is Maintained at Overweight by Barclays

Dow JonesJul 25, 2022 08:44 ET

Barclays Maintains Overweight on Dr Reddy's Laboratories, Lowers Price Target to $68

Benzinga Real-time NewsJul 25, 2022 08:34 ET

Dr. Reddy's Laboratories Target Price Raised to INR4,750 From INR4,500 by Axis Securities

Dow JonesJun 28, 2022 04:02 ET